Clinical implications of inhibition of the late sodium current: Ranolazine

European Heart Journal, Supplement

Volumn 8, Issue A, 2006, Pages

  Bassand, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Anti ischemic agents; Chronic stable angina; Exercise stress testing; Ranolazine

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NIFEDIPINE; NITRATE; PERINDOPRIL; POTASSIUM CHANNEL STIMULATING AGENT; RAMIPRIL; RANOLAZINE; TRIMETAZIDINE;

ANGINA PECTORIS; ARTICLE; ASTHENIA; BLEEDING; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXERCISE; HEADACHE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART RATE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; SODIUM CURRENT; STABLE ANGINA PECTORIS; SUSTAINED DRUG RELEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

EID: 31644449070     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui092     Document Type: Article

References (39)

1. American Heart Association, American Stroke Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Texas: American Heart Association; 2005.
2. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. JAMA 1997;277:715-721.
3. Holubkov R, Laskey WK, Haviland A et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002;144:826-833.
4. Serruys PW, Unger F, Sousa JE et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
5. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-168.
6. Julian DG, Bertrand ME, Hjalmarsson A et al. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
7. Paulus WJ, Serizawa T, Grossman W. Altered left ventricular diastolic properties during pacing-induced ischemia in dogs with coronary stenoses: potentiation by caffeine. Circ Res 1982;50:218-227.
8. Paulus WJ, Grossman W, Serizawa T et al. Different effects of two types of ischemia on myocardial systolic and diastolic function. Am J Physiol 1985;248:H719-H728.
9. Serizawa T, Carabello BA, Grossman W. Effect of pacing-induced ischemia on left ventricular diastolic pressure-volume relations in dogs with coronary stenoses. Circ Res 1980;46:430-439.
10. McLaurin LP, Rolett EL, Grossman W. Impaired left ventricular relaxation during pacing-induced ischemia. Am J Cardiol 1973;32: 751-757.
11. Dwyer EM Jr. Left ventricular pressure-volume alterations and regional disorders of contraction during myocardial ischemia induced by atrial pacing. Circulation 1970;42:1111-1122.
12. Barry WH, Brooker JZ, Alderman EL, Harrison DC. Changes in diastolic stiffness and tone of the left ventricle during angina pectoris. Circulation 1974;49:255-263.
13. Grossman W, Mann JT. Evidence for impaired left ventricular relaxation during acute ischemia in man. Eur J Cardiol 1978;7(Suppl.):239-249.
14. Bourdillon PD, Lorell BH, Mirsky I et al. Increased regional myocardial stiffness of the left ventricle during pacing-induced angina in man. Circulation 1983;67:316-323.
15. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-910.
16. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004;6(Suppl. I):I3-I7.
17. Haigney MC, Lakatta EG, Stern MD, Silverman HS. Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation 1994;90:391-399.
18. Roden DM. Cardiac membrane and action potentials. In: Spooner PM, Rosen MR, eds. Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. New York: Marcel Dekker; 2001. p21-41.
19. Ver Donck L, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc Res 1993;27:349-357.
20. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
21. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
23. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
24. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
25. Savonitto S, Ardissiono D, Egstrup K et al. Combination therapy with metoprolol and nifedipine vs monotherapy in patients with stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311-316.
26. Heidenreich PA, McDonald KM, Hastie T et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-1936.
27. Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849-857.
28. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-1275.
29. Dalla-Volta S, Maraglino G, Della-Valentina P et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(Suppl. 4):853-859.
30. Chazov El, Lepakchin VK, Zharova EA et al. Trimetazidine in Angina Combination Therapy-the TACT study: trimetazidine vs conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35-42.
31. Rihal CS, Raco D, Gersh BJ, Yusuf S. Impact of revascularization procedures in chronic coronary artery disease on clinical outcomes: a critical review of the evidence. In: Yusuf S, Camm J, Cairns J et al., eds. Evidence-based Cardiology. London: BMJ Books; 2002. p339-359.
32. Serruys PW. Arterial Revascularization Therapies Study Part II (ARTS II) of the sirolimus eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2005;45:7A.
33. Daly CA, Clemens F, Sendon JL et al. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:1011-1022.
34. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine vs atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-316.
35. Cocco G, Rousseau MF, Bouvy T et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-138.
36. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 1999;84:46-50.
37. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382.
38. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316.
39. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-48.